Found Review
GLP-1 platform that pairs medication with one-on-one coaching and a broad off-label formulary.
Reader-supported, we may earn a commission through links on this site. Rankings are editorially independent. Disclosure · Methodology
Quick Verdict
GLP-1 platform that pairs medication with one-on-one coaching and a broad off-label formulary.
Who it's for: Found is best for buyers who know they want behavior-change support alongside medication, and who appreciate options beyond GLP-1 (metformin, bupropion-naltrexone) when those are clinically appropriate. The behavior-change coaching is the main differentiator over pure medication platforms — Found suits buyers who have tried medication-only approaches without sustained results and want more accountability.
Bottom line: One of the more coaching-forward GLP-1 telehealth options. Pricing tiers can confuse first-time buyers; verify the cancellation terms before subscribing. Pricing tiers can confuse first-time buyers; verify the cancellation policy before subscribing. If you want the lowest possible cost for compounded GLP-1 without coaching, Trimi or HealthRx will be significantly cheaper.
- One-on-one coaching included
- Broad medication formulary beyond GLP-1
- Insurance navigation for brand-name drugs
- Confusing multi-tier pricing
- $99 early-cancellation fee
- Customer support can be slow at peak
Pros & Cons In Detail
Found Pricing
Telehealth ads often advertise a low headline price that's the clinic's program fee, not the medication. Here's how the two line items break down at Found.
| Program / Membership Fee | Included in monthly plan |
| Medication Cost (From) | From $129 – $349/mo |
Found offers two paths, a coaching-only Wellness path and an Rx path that combines medication with coaching. Brand-name GLP-1s are billed separately at manufacturer list prices and an early-cancellation fee may apply.
Who Found Is For
Found is best for buyers who know they want behavior-change support alongside medication, and who appreciate options beyond GLP-1 (metformin, bupropion-naltrexone) when those are clinically appropriate. The behavior-change coaching is the main differentiator over pure medication platforms — Found suits buyers who have tried medication-only approaches without sustained results and want more accountability.
Adults who want medication paired with one-on-one coaching and behavior change, not just a prescription drop.
Signature Programs
- ›Rx Path with medication plus coaching
- ›Wellness Path with coaching only
- ›Insurance navigation for brand-name GLP-1s
Medication Formulary
The Bottom Line
One of the more coaching-forward GLP-1 telehealth options. Pricing tiers can confuse first-time buyers; verify the cancellation terms before subscribing. Pricing tiers can confuse first-time buyers; verify the cancellation policy before subscribing. If you want the lowest possible cost for compounded GLP-1 without coaching, Trimi or HealthRx will be significantly cheaper.
With an editor score of 4.2 / 5 across cost, experience, and trust, Found is one of the strong mid-tier options in the glp-1 weight loss category we cover.
See how Found compares in our full glp-1 weight loss rankings, or read the Best Telehealth GLP-1 Providers guide. Our methodology explains how we score each provider.
Frequently Asked Questions
- Wilding et al., NEJM 2021 (STEP 1) · Semaglutide 2.4 mg produced 14.9% mean weight loss vs 2.4% placebo at 68 weeks in the STEP 1 trial.
- FDA Federal Register 2024 (Semaglutide shortage end) · FDA removed semaglutide from the drug shortage list in October 2024, ending the legal basis for compounding.
- Jastreboff et al., NEJM 2022 (SURMOUNT-1) · Tirzepatide 15 mg produced 20.9% mean weight loss vs 3.1% placebo at 72 weeks in SURMOUNT-1.
- FDA Federal Register 2024 (Tirzepatide shortage end) · FDA removed tirzepatide from the drug shortage list in October 2024.
- Wharton et al., NEJM 2025 (ATTAIN-1 -- orforglipron) · Oral orforglipron 36 mg produced 7.9% mean weight loss vs 1.5% placebo at 40 weeks in the ATTAIN-1 phase 3 trial.
- Lincoff et al., NEJM 2023 (SELECT -- semaglutide cardiovascular) · Semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% vs placebo in the SELECT trial of 17,604 adults with overweight/obesity.
RxNotebook is an editorial publication. Citations point to peer-reviewed journals, FDA labeling, and clinical society guidelines. We are not affiliated with the studies cited above. This page is for general information and is not medical advice.